ZD4054

ZD4054 is a drug that was under development by AstraZeneca for the treatment of metastatic hormone-refractory prostate cancer. It is an endothelin receptor antagonist, specifically targeting the endothelin A receptor.

Development[edit | edit source]

ZD4054 was in Phase III clinical trials for the treatment of metastatic hormone-refractory prostate cancer. However, in 2010, AstraZeneca announced that it was discontinuing the development of the drug due to lack of efficacy in clinical trials.

Mechanism of Action[edit | edit source]

ZD4054 works by blocking the endothelin A receptor. Endothelin is a protein that constricts blood vessels and raises blood pressure. By blocking the action of endothelin, ZD4054 can help to slow the growth of cancer cells and reduce the size of tumors.

Clinical Trials[edit | edit source]

In Phase II clinical trials, ZD4054 showed promise in slowing the progression of metastatic hormone-refractory prostate cancer. However, in Phase III trials, the drug did not meet its primary endpoint of improving overall survival.

Side Effects[edit | edit source]

The most common side effects of ZD4054 include nausea, vomiting, diarrhea, and fatigue. Less common side effects include headache, dizziness, and shortness of breath.

See Also[edit | edit source]

ZD4054 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.